View this email in your browser
Facebook
Twitter
LinkedIn
Vimeo
SoundCloud
Dear Colleagues,

Lifescience entrepreneurs: be sure to register for the Tuesday, March 21st, Life Science Entrepreneurship event featuring Regeneron’s founding team George Yancopoulos and Leonard Schleifer in discussion with Columbia’s Tom Maniatis. This promises to be a fantastic conversation, more info and registration link below in the Featured Event section, registration link here.

I am also excited to share news about two recent agreements for Columbia technologies.
  • Lin BioScience, Columbia University and Memorial Sloan Kettering Cancer Center, have reached a worldwide exclusive licensing agreement for a novel inhibitor of CDC7 kinase relevant for a wide range of cancers. Read the full story here.
  • We are also pleased that Applied Therapeutics closed its Series A financing round, proceeds from which will be used to pursue clinical development of technology licensed earlier this year from Columbia University. The technology, developed by Donald Landry, M.D., Ph.D., Chair of the Department of Medicine at Columbia University, targets enzymes implicated in metabolic and cardiovascular disease. Read the full story here.
Finally, we are gratified to share that Columbia has been ranked top 5 in the country for life science licensing and startups by Nature. Read the full report here.


Best wishes,

Orin Herskowitz
Executive Director, CTV
Senior VP for Intellectual Property & Technology Transfer
FEATURED VIDEOS
 
Panel discussion with Garrard Beeney (Partner and Co-Head of the Intellectual Property and Technology Group at Sullivan & Cromwell), Ian McClure (Director at the Office of Technology Commercialization at the University of Kentucky, and former IPXI), Phil Hartstein (President and CEO of Finjan), John Veschi (CEO of Marquis Technologies and Former CEO of Rockstar), and Jeff Sears (Associate General Counsel and Chief Patent Counsel at Columbia University) discuss the future of IP and changes in licensing landscape cased by the new patent laws; provide their advice for startups who believe their IP is being infringed by large companies; and talk about patent strategies for tech startups vs. biopharma startups. Watch it here. Listen to the podcast here.
John Veschi, CEO of Marquis Technologies and former CEO of the Rockstar Consortium, the company backed by Apple, Microsoft, Sony, and others to monetize the Nortel patent portfolio. John discusses his role at Bell Labs and Alcatel-Lucent, management of patents at Nortel, and the opportunities and challenges of launching Rockstar. Watch it here.
Garrard Beeney, Partner and Co-head of Sullivan & Cromwell’s IP practice, explaining patent pools; the problems that they are designed to overcome (royalty stacking, holdouts); how they manage anti-competitive issues; what are industry standards, and therefore “standard-essential” patent pools. Watch it here.
Ian McClure, Director at the Office of Technology Commercialization at the University of Kentucky, and one of the founding team of IPXI.  IPXI was a novel experiment in building a financial exchange (based on the Chicago commodities exchange) for buying and selling IP rights in a litigation-free environment.  Ian explains why IPXI was formed, what challenges it tried to address, and why it ultimately was disbanded. Watch it here.
Phil Hartstein, President and CEO of Finjan, discusses his early career prior to joining Finjan; how to determine what percentage of a startup’s budget should be set aside for IP filings; the role of an IP portfolio for fundraising; how Finjan was formed initially as an operating cybersecurity company; why Finjan’s patent portfolio was eventually spun-out into a publicly-traded IP pure play; and whether being a public company is beneficial for IP pure plays. Watch it here.
FEATURED EVENT
Tuesday March 21st- Please join the Precision Medicine Initiative at Columbia University this spring as it hosts the first event of the Life Science Entrepreneurship seminar series. The first class Regeneron: The Path from Basic Research to Commercial Product will cover topics such as: Target Patient, Value Proposition and Forecasting; Attracting Investors; Clinical Development and Regulatory Pathway, with a special presentation by Regeneron's founding team George Yancopoulos and Leonard Schleifer. Register Here.
FEATURED OPPORTUNITIES
Sunday April 2nd- The SunRISE TechBridge Challenge II, sponsored by DSM and presented in collaboration with Greentown Labs, is a program to accelerate innovative solutions that will reduce the levelized cost of energy (LCOE) for photovoltaic (PV) systems. The areas of interest broadly include novel PV cell and module materials, data analytics software and advanced sensors, and retrofit solutions. Apply by April 2nd here.

Monday April 24th - 2017 Women Entrepreneurs Boot Camp - Spend an interactive and thought-provoking day at the second annual Women Entrepreneurs Boot Camp (WEB). Up to 30 women founders will be invited to participate in a day-long immersive program designed to impart practical advice and develop actionable skills. Apply by April 7th here.
#ColumbiaInnovation
Alternative indication for clinically-approved drug to treat osteoporosis and low bone mass | Learn more

Small molecule inhibitor for more precise biotin/streptavidin tagging affords improved live cell imaging | Learn more

Soft robotic actuators based on highly expansive elastomers | Learn more

Method for DNA fingerprinting using handheld DNA sequencers | Learn more

Patient-specific neck brace with dynamic range of motion | Learn more

Columbia University has over 1200 active patent assets available for licensing. Click here to discover more
Have something you'd like to see included? Email techventuresmedia@columbia.edu
Copyright © 2017 Columbia Technology Ventures, All rights reserved. 

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list